-
22
patients randomized in 12 months, about 30% of trial
enrollmentPhase 3, ultra-rare disease
Prescreened 82Screened 46Randomized 22
-
14
participants enrolled through advocacy outreach, 18% of
trial enrollmentRare oncology
17 patient advocacy DOLs engaged144 discussion guides downloaded95 prescreeners in 7 months
-
24
patients randomized in 9 months in a program supporting 50
US and Canadian sitesPhase 2, neurodegenerative disease
Prescreened 250Screened 52Randomized 24
-
77
digital opinion leaders profiled and tracked for a digital
therapeutic launchDigital therapeutic
160 clinicians surveyed on credibility10+ leaders engaged in the launch
-
40
digital opinion leaders posting about osteoporosis
identified for a planned brand launchOsteoporosis
Filtered by geography, language, recency and channelTracked through their social feeds